Unknown Manufacturer
Umbilical-cord derived MSCs are currently being tested for numerous clinical applications due to their immunosuppressive and anti-inflammatory properties. In comparison to bone-marrow derived MSCs, these cells are more resilient, easier to extract, and generally regarded as less immunogenic. The condition medium (CM) derived from these MSCs has also been implicated in therapeutic properties. Once MSCs are isolated from the tissue through extraction procedures, they are cultured in the Dulbecco’s Modified Eagle’s Medium (DMEM) to separate soluble factors into the liquid. Many companies are creating their own version of this medium. One of these companies, Aspire, has created their own product, ACT-20 Conditioned Medium as a product for testing.
Umbilical-cord derived MSCs are currently being tested for numerous clinical applications due to their immunosuppressive and anti-inflammatory properties. In comparison to bone-marrow derived MSCs, these cells are more resilient, easier to extract, and generally regarded as less immunogenic. The condition medium (CM) derived from these MSCs has also been implicated in therapeutic properties. Once MSCs are isolated from the tissue through extraction procedures, they are cultured in the Dulbecco’s Modified Eagle’s Medium (DMEM) to separate soluble factors into the liquid. Many companies are creating their own version of this medium. One of these companies, Aspire, has created their own product, ACT-20 Conditioned Medium as a product for testing.
The factors contained in the CM are thought to hold differentiation and therapeutic function, additionally, they may also intensify the positive effects of cell-based therapies. Some of the growth factors and cytokines found include IL-6, VEGF, angiogenin, and IGF-1. Through these factors, the conditioned medium exerts numerous effects, including accelerated wound healing, anti-photo aging, and induced differentiation.
